Heart Scan to Guide Plaque Care in Men With Prostate Cancer
Tests a heart CT scan to guide plaque treatment in men on hormone therapy.
Plain-language title generated from the registry record
Registry title: ASCVD Management Using CCTA in Prostate Cancer Patients on ADT
Key facts
- Where
- Carmel and Indianapolis, United StatesSee the 3 sites
Where in United States
- IU Health Joe and Shelly Schwarz Cancer CenterCarmel, United StatesTaking people
- Indiana University Melvin and Bren Simon Comprehensive Cancer CenterIndianapolis, United StatesTaking people
- Methodist HospitalIndianapolis, United StatesTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Indiana University
- Trial code
- NCT05879913
- Record updated
- 5 October 2026
- Original description
This is a randomized pilot study of Coronary CT Angiography (CCTA) for coronary atherosclerosis vs. Usual Care in patients with prostate cancer who are either planning to begin, or are currently taking androgen deprivation therapy (ADT) .Read full original descriptionShow less
Personalized Medical Treatment of Coronary Atherosclerosis in Prostate Cancer Patients Guided by Plaque Assessment With Quantitative Coronary CT Angiography (CCTA)
This is a randomized pilot study of Coronary CT Angiography (CCTA) for coronary atherosclerosis vs. Usual Care in patients with prostate cancer who are either planning to begin, or are currently taking androgen deprivation therapy (ADT) .
Inclusion: Written informed consent and HIPAA authorization for release of personal health information; Age ≥40 years at time of consent; Previous diagnosis of prostate cancer who are either currently receiving ADT, or who are planning to start ADT for >12 months; Patients currently on or planned for treatment with ADT plus androgen pathway inhibitor (abiraterone, enzalutamide, apalutamide, darolutamide) are allowed; ≥1 risk factor for ASCVD (hypertension, hyperlipidemia, diabetes, tobacco use); No current cardiac symptoms.
Exclusion: Concurrent treatment with chemotherapy (docetaxel, cabazitaxel, mitoxantrone) at time of signing consent; History of coronary stents, obstructive coronary artery disease, myocardial infarction, coronary artery bypass grafting. History of atrial fibrillation; Allergy to iodinated contrast; Contraindication to the medications that may be given to regulate heart rate for the CCTA scan (applicable only to those randomized to the CCTA group); Patients taking sildenafil or tadalafil for vasodilation, pulmonary hypertension, or BPH; Note: Subjects taking sildenafil or tadalafil for erectile disfunction will still be eligible; Renal dysfunction with creatinine clearance <35ml/min (calculated by Cockcroft-Gault Equation); Patient has implantable cardioverter-defibrillator (ICD), or pacemaker.